Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Childhood Non-Hodgkin Lymphoma (NHL)
- Histopathologic and Molecular Classification of Childhood NHL
- Stage Information for Childhood NHL
- Treatment Option Overview for Childhood NHL
- Aggressive Mature B-cell NHL
- Lymphoblastic Lymphoma
- Anaplastic Large Cell Lymphoma
- Lymphoproliferative Disease Associated With Immunodeficiency in Children
- Rare NHL Occurring in Children
- Changes to This Summary (03/30/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (03/30/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised Table 3 to include chemotherapy with or without rituximab as a treatment option for lymphoproliferative disease associated with primary immunodeficiency and to include rituximab with or without chemotherapy as a treatment option for marginal zone lymphoma.
Revised text to state that pediatric patients had a 3-year event-free survival of 81% and a 3-year overall survival of 91%. These results were not significantly different from the results observed in adults.
Revised text about the patient characteristics and results of a phase II study of adults and adolescents with CD30-positive anaplastic large cell lymphoma who were treated with brentuximab vedotin.
Added text to state that although the number of pediatric patients with HIV-associated NHL is too small to perform meaningful clinical trials, studies of adult patients support the addition of rituximab to standard regimens (cited Besson et al. as reference 11).
Added text to state that although the number of pediatric patients with pediatric follicular-type lymphoma is too small to perform meaningful clinical trials, studies of adult patients with follicular lymphoma support the addition of rituximab to standard regimens.
The Marginal Zone Lymphoma (Including MALT Lymphoma) subsection was extensively revised.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
No hay comentarios:
Publicar un comentario